TransMedics(US:TMDX) The Motley Foolยท2024-12-03 17:39Core Insights - TransMedics' shares fell by 14% following a positive announcement regarding the hiring of a new CFO, due to tempered revenue expectations for 2024 [1][2] - The company now projects 2024 revenue between $428 million and $432 million, indicating a growth of 77% to 79% compared to the previous year, which is lower than prior guidance [2][3] - Following a disappointing Q3 earnings report, where the company maintained market share but did not grow as expected, investors were looking for a rebound in Q4 [3] Financial Performance - The new guidance suggests a 35% sales growth rate for Q4, significantly lower than the triple-digit growth rates seen in 10 of the last 11 quarters [3] - TransMedics' shares have decreased by 59% from their highs, trading at 6.3 times sales, the lowest since going public in 2019 [4] Market Position and Future Outlook - Despite the slowdown in growth, TransMedics remains a leader and first mover in the organ transplant industry [4] - An analyst day is scheduled for December 10, which is expected to provide new insights and guidance for the company moving forward [5]